|
Vaccine Detail
Recombinant Vaccinia PSA Vaccine |
Vaccine Information |
- Vaccine Name: Recombinant Vaccinia PSA Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007163
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- KLK3
gene engineering:
- Type: Recombinant protein preparation
- Description: (Eder et al., 2000)
- Detailed Gene Information: Click Here.
- Preparation: PSA gene is inserted into the viral genome of vaccinia (Eder et al., 2000).
- Description: This is for Prostate Cancer (NCT02649439). A vaccine consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA). Vaccination with recombinant vaccinia prostate-specific antigen vaccine stimulates the host immune system to mount a cytotoxic T-cell response against tumor cells expressing PSA (Gulley et al., 2002; NCIT_C2433).
|
Host Response |
|
References |
Eder et al., 2000: Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000; 6(5); 1632-1638. [PubMed: 10815880].
Gulley et al., 2002: Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. The Prostate. 2002; 53(2); 109-117. [PubMed: 12242725].
NCIT_C2433: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2433]
NCT02649439: [https://clinicaltrials.gov/show/NCT02649439/]
|
|